<DOC>
	<DOCNO>NCT00006357</DOCNO>
	<brief_summary>RATIONALE : STI571 may interfere growth cancer cell may effective treatment soft tissue sarcoma . PURPOSE : Phase I/II trial study effectiveness STI571 treat patient recurrent refractory soft tissue sarcoma .</brief_summary>
	<brief_title>STI571 Treating Patients With Recurrent Refractory Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose associate toxicity STI571 patient refractory recurrent soft tissue sarcoma . II . Determine pharmacokinetic profile treatment regimen patient . III . Determine objective response duration response patient treatment regimen . OUTLINE : This dose escalation dose efficacy , multicenter study . In dose efficacy portion , patient stratify accord disease type ( gastrointestinal stromal tumor v soft tissue sarcoma ) . Phase I : Patients receive oral STI571 daily maximum 24 month absence disease progression unacceptable toxicity . Cohorts 3-8 patient receive escalate dos STI571 maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6-8 patient experience dose limit toxicity . The recommended phase II dose define dose precede MTD . Phase II : Patients receive recommend phase II dose STI571 phase I . Patients follow every 8 week disease progression , every 16 week thereafter . PROJECTED ACCRUAL : Approximately 47-72 patient ( 7-32 phase I 40 phase II ) accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm soft tissue sarcoma Malignant fibrous histiocytoma Liposarcoma Rhabdomyosarcoma Synovial sarcoma Malignant paraganglioma Fibrosarcoma Leiomyosarcoma Angiosarcoma Hemangiopericytoma Neurogenic sarcoma Unclassified sarcoma Miscellaneous sarcoma ( include mixed mesodermal tumor uterus ) Gastrointestinal stromal tumor ( GIST ) ( must ckit positive ) No malignant mesothelioma , chondrosarcoma , neuroblastoma , osteosarcoma , Ewing 's sarcoma , embryonal rhabdomyosarcoma Phase I study nonGIST phase II study patient : Must receive one prior first line combination chemotherapy regimen two first line single agent regimen Adjuvant chemotherapy consider first line , unless disease progression within 6 month treatment Phase II GIST patient : No one prior first line combination chemotherapy regimen two first line single agent regimen Adjuvant chemotherapy consider first line , unless disease progression within 6 month treatment Measurable disease evidence progression past 6 week Osseous lesion pleural effusion consider measurable No symptomatic know CNS metastases PATIENT CHARACTERISTICS : Age : 15 Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.8 mg/dL Albumin least 25 g/L Renal : Creatinine great 1.4 mg/dL OR Creatinine clearance great 65 mL/min Cardiovascular : No history cardiovascular disease Other : No prior concurrent second primary malignant tumor except adequately treat carcinoma situ cervix basal cell carcinoma No severe illness ( include psychosis ) Not pregnant Fertile patient must use effective contraception 6 month follow study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy No concurrent local systemic chemotherapy Endocrine therapy : No concurrent systemic corticosteroid therapy Radiotherapy : No prior radiotherapy sole index lesion Concurrent radiotherapy lesion allow sole target lesion Surgery : Not specify Other : No prior embolization sole index lesion No concurrent investigational drug No concurrent warfarin</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>adult angiosarcoma</keyword>
	<keyword>adult fibrosarcoma</keyword>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>adult liposarcoma</keyword>
	<keyword>adult neurofibrosarcoma</keyword>
	<keyword>adult synovial sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>small intestine leiomyosarcoma</keyword>
	<keyword>adult alveolar soft-part sarcoma</keyword>
	<keyword>adult epithelioid sarcoma</keyword>
	<keyword>adult malignant fibrous histiocytoma</keyword>
	<keyword>adult malignant hemangiopericytoma</keyword>
	<keyword>adult malignant mesenchymoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>uterine carcinosarcoma</keyword>
	<keyword>uterine leiomyosarcoma</keyword>
	<keyword>endometrial stromal sarcoma</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>gastrointestinal stromal tumor</keyword>
</DOC>